FDA Approves Fresenius Kabi's Tyenne, a Biosimilar of Actemra for the Treatment of …

Back in November, Fresenius Kabi launched Tyenne after receiving … pain (15%; 2%), chills (8%; 0%), anemia (45%; 38%), febrile neutropenia (28 …
Source: back pain